RT Journal Article
SR Electronic
A1 Sinclair, Heather Q.
T1 Apixaban Reduces Stroke Risk in Patients with AF: Results from the AVERROES Trial
JF MD Conference Express
YR 2010
FD SAGE Publications
VO 10
IS 8
SP 14
OP 14
DO 10.1177/155989771008010
UL http://mdc.sagepub.com/content/10/8/14.abstract
AB The oral direct factor Xa inhibitor apixaban was superior to aspirin therapy for the reduction of stroke or systemic embolism risk in patients with atrial fibrillation who were unsuitable for vitamin K antagonist therapy according to the phase III Apixaban versus Acetylsalicylic Acid to Prevent Strokes [AVERROES; NCT00496769] trial.